Amgen to price tap of 2027, 2040, 2050 notes, new notes due 2031

By Marisa Wong

Los Angeles, May 4 – Amgen Inc. plans to offer new senior notes due 2031 and further issuances of its 2.2% senior notes due 2027, 3.15% senior notes due 2040 and 3.375% senior notes due 2050, according to a 424B3 filing with the Securities and Exchange Commission.

The 2027 notes, 2040 notes and 2050 notes are add-ons to Amgen’s $750 million 2.2% notes due 2027, $1.25 billion 3.15% notes due 2040 and $1.25 billion 3.375% notes due 2050 issued on Feb. 21. The additional notes will form a single series with the existing notes.

BofA Securities, Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC are the underwriters.

Proceeds will be used for general corporate purposes.

Amgen is a Thousand Oaks, Calif., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.